Tenderwize
Zurück zur Suche

Open-house pharmaceutical discount agreement for Eribulin

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 16, 2027 · 264 days left·Open·Supplies·Framework
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Eribulin, ATC L01XX41

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

Paper submissions require duplicate original signed documents, and electronic submissions require a qualified electroni...

Eligibility is limited to pharmaceutical companies and requires a signed reliability declaration.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Open-house supply arrangement for pharmaceutical products, specifically Eribulin (ATC L01XX41).
  • Non-exclusive discount agreements under § 130a Abs. 8c SGB V for parenteral preparations made from finished medicinal products in oncology.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Eribulin (CPV 33600000) in Bavaria, not a competitive award procedure. The contracting buyers are led by AOK Bayern, with several other sickness funds participating. Any interested pharmaceutical company may join if it meets the stated eligibility requirement and submits the required signed documents. The contract term runs from 01.08.2025 to 31.07.2027, with applications possible until 16.05.2027. Submission is allowed electronically via DTVP with qualified electronic signature or in paper form by original signed copies.

Risiken

Paper submissions require duplicate original signed documents, and electronic submissions require a qualified electroni...

Eligibility is limited to pharmaceutical companies and requires a signed reliability declaration.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a completed and signed self-declaration on reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed file 'OHV_8c_Bayern_Festlegung_PZN'.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house pharmaceutical discount agreement for Eribulin

Open-house, non-exclusive discount agreement for Eribulin (ATC L01XX41) for extemporaneously prepared parenteral oncology preparations for immediate physician use in Bavaria. The notice states that all interested pharmaceutical companies meeting the eligibility condition may conclude identical, non-negotiable agreements. The lot information comes from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Frist

Deadline May 16, 2027

Vergabedetails

Veröffentlichungsdatum
19 May 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
324154-2025

Dokumente (2)

Ähnliche Ausschreibungen